Grant Number:	5R03CA099897-02 Interpret this number
Primary Investigator:	Vaughan, Thomas
Organization:	Fred Hutchinson Can Res Ctr
Project Title:	Insulin-Like Growth Factors & Esophageal Adenocarcinoma
Fiscal Year:	2003

DESCRIPTION (provided by applicant): Insulin-like growth factors (IGFs) are potent mitogens that play pivotal roles in regulation of cell proliferation, differentiation and apoptosis. IGFs implement their role through interactions with several molecules, including IGF-1 receptors on the cell membrane (in particular, IGF-1R) and several IGF binding proteins (notably IGFBP-3). In addition, polymorphisms in IGF-1, IGF-1R and IGFBP-3 genes have been identified that may have functional significance with regard to tissue concentrations of IGFs. Increased serum concentrations of IGFs, along with decreased concentrations of IGFBP-3, recently have been reported to increase risk of several cancers. We propose to take advantage of data and specimens collected in an ongoing cohort study of predictors of neoplastic progression in persons with Barrett's esophagus (BE) (n = 420, up to 8 years of follow up) to determine whether IGFs are related to risk of esophageal adenocarcinoma (EA), and a series of biomarkers validated as predictors of EA. The subjects donated blood and underwent endoscopic biopsies, physical examination and interview at baseline. Regular follow-up endoscopies and biopsies have been performed since baseline. Aim 1 will determine whether increased baseline serum levels of IGF-1 and decreased levels of IGFBP-3 are associated with increased risk of neoplastic progression in BE. Neoplastic progression will be determined by the development of EA, high-grade dysplasia, increased 4N/G2 fractions, aneuploidy and/or 17pLOH. Aim 2 will determine whether polymorphisms in IGF-1, IGF-1 receptor and IGFBP-3 genes are related to risk of neoplastic progression, and whether they modify any associations observed in the first aim. Secondary aims will investigate whether observed IGF associations are modified by key risk factors for EA and BE, including obesity, waist:hip ratio, and use of NSAIDs, serum selenium and menopausal status. Cox regression models will be used to calculate adjusted hazard ratios. Our well-established and characterized cohort, together with data and tissue that are readily available, afford a unique and cost-efficient opportunity to study these issues, with the expectation that positive results would provide i) additional methods with which to identify high risk subjects with BE for more frequent surveillance, and ii) modifiable factors for short-term intervention studies.





None